Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 101–200 of 1,871
Cesaro, A., Pastori, D., Acerbo, V., Biccirè, F. G., Golino, M., Panico, D., Prati, F., Abbate, A., Lip, G. Y. H., & Calabrò, P. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf257 · Cited by 56
Theodorakis, N., & Nikolaou, M. (2025) · Biomedicines · doi:10.3390/biomedicines13010135 · Cited by 50
Tirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
“Additionally, for people with T2D and CKD, semaglutide 1 mg weekly reduced major kidney disease events by 24% versus placebo [75].”
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
Natividade, G. R., Spiazzi, B. F., Baumgarten, M. W., Bassotto, C., Pereira, A. A., Fraga, B. L., Scalco, B. G., Mattes, N. R., Lavinsky, D., Kramer, C. K., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2489 · Cited by 41
Finerenone in Type 1 Diabetes and Chronic Kidney Disease
Heerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Groop, P., Ji, L., Jongs, N., Mathieu, C., Pratley, R. E., Rosas, S. E., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2512854 · Cited by 52
Self-citationUnraveling Diabetic Kidney Disease: The Roles of Mitochondrial Dysfunction and Immunometabolism
Narongkiatikhun, P., Choi, Y. J., Hampson, H. E., Gotzamanis, J., Zhang, G., van Raalte, D. H., de Boer, I. H., Nelson, R. G., Tommerdahl, K. L., McCown, P. J., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.09.019 · Cited by 45
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“…study in people ( n = 3533) with type 2 diabetes and chronic kidney disease, (Table 2) the weight loss was −5.6% and −1.5% with semaglutide 2.4 mg and placebo, respectively, and semaglutide reduced the risk of clinical important kidney outcome and cardiovascular death compared with placebo [51].”
InfluentialScreening for chronic kidney disease: change of perspective and novel developments
van Mil, D., Kieneker, L. M., Heerspink, H. J. L., & Gansevoort, R. T. (2024) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001016 · Cited by 56
ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases
Ikizler, T. A., Kramer, H., Beddhu, S., Chang, A. R., Friedman, A. N., Harhay, M. N., Jimenez, E. Y., Kistler, B. M., Kukla, A., Larson, K., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000512 · Cited by 44
Orandi, B. J., Chen, Y., Li, Y., Charyton, D., Lentine, K. L., Lee, B. P., Ali, N., DeMarco, M. P., Weintraub, M. A., Bae, S., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000750 · Cited by 38
Dedov, I., Shestakova, M., Sukhareva, O., Mokrysheva, N., Andreeva, E., Bezlepkina, O., Peterkova, V., Artemova, E., Bardiugov, P., Bessmertnaya, E., et al. (2025) · Diabetes Mellitus · doi:10.14341/dm20255s · Cited by 61
Edmonston, D. L., Mulder, H. S., Lydon, E. J., Chiswell, K., Lampron, Z. M., Shay, C. M., Marsolo, K. A., Shah, R. C., Jones, W. S., Gordon, H. S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.016 · Cited by 47
ABCDE to identify and prevent chronic kidney disease: a call to action
Ferro, C. J., Wanner, C., Luyckx, V. A., Stevens, K., Cerqueira, S. A., Darwish, R. A., Fernández‐Fernández, B., Fiel, D., Filev, R., Grieger, M., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf057 · Cited by 55
“…antagonists (nsMRAs) [70 ], sodium–glucose co-transporter 2 inhibitors (SGLT2is) [71 ] and glucagon-like peptide-1 receptor antagonists (GLP-1ras) [72 ] have been tested in large randomized controlled trials showing very significantly improved cardiovascular and kidney outcomes in individuals…”
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
Pantazopoulos, D., Gouveri, E., Papazoglou, D., & Παπάνας, Ν. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112924 · Cited by 53
Beernink, J. M., van Mil, D., Laverman, G. D., Heerspink, H. J. L., & Gansevoort, R. T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16359 · Cited by 59
“152 In recent years, large observational cohort studies have consistently shown that, in addition to baseline albuminuria levels, changes in albuminuria are strongly associated with the risk of progression to kidney failure.”
Duah, J., & Seifer, D. B. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-024-01339-y · Cited by 54
Westermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 45
Karakasis, P., Fragakis, N., Patoulias, D., Theofilis, P., Sagris, Μ., Koufakis, T., Vlachakis, P. K., Rangraze, I. R., El‐Tanani, M., Tsioufis, K. P., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092112 · Cited by 41
“Furthermore, GLP-1RAs have demonstrated reductions in renal inflammation and preservation of renal structure and function, as evidenced by findings from the recent FLOW trial [58].”
BackgroundMetabolic dysfunction–associated kidney disease: pathogenesis and clinical manifestations
Bansal, A., & Chonchol, M. (2025) · Kidney International · doi:10.1016/j.kint.2025.01.044 · Cited by 46
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 85
Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes
Chaiyakunapruk, N., Tan, X., Liang, Y. M., Guevarra, M., Xie, L., & CHENG, A. Y. Y. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02737-1 · Cited by 47
“In the FLOW trial, semaglutide was associated with a reduced risk of kidney failure and a reduction in the decline of eGFR among participants with T2D and CKD; no significant differences were observed between those with or without SGLT2i use at baseline [20].”
Brazilian Guidelines of Hypertension – 2025
Brandão, A. A., Rodrigues, C. I. S., Bortolotto, L. A., Armstrong, A. D. C., Mulinari, R. A., Feitosa, A. D. M., Gomes, M. A. M., Barbosa, E. C. D., Moura-Neto, J. A., Neves, M. F., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250624 · Cited by 156
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Ryan, D. H. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09967-4 · Cited by 34
Shah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Neves, J. S., Leite, A. R., Mentz, R. J., Holman, R. R., Zannad, F. M., Butler, J., Packer, M., & Ferreira, J. P. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3478 · Cited by 44
Type 2 Diabetes and the Multifaceted Gut-X Axes
Guo, H., Pan, L.-T., Wu, Q., Wang, L., Huang, Z., Wang, J., Wang, L., Fang, X., Dong, S., Zhu, Y., et al. (2025) · Nutrients · doi:10.3390/nu17162708 · Cited by 44
Unraveling Sex Differences in Kidney Health and CKD: A Review of the Effect of Sex Hormones
van Eeghen, S. A., Nokoff, N., Vosters, T. G., Oosterom-Eijmael, M. J. P., Cherney, D. Z. I., van Valkengoed, I. G. M., Choi, Y. J., Pyle, L. L., Bjornstad, P., den Heijer, M., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000642 · Cited by 46
From fat to filter: the effect of adipose tissue-derived signals on kidney function
Ahmed, N., Dalmasso, C., Turner, M. B., Arthur, G., Cincinelli, C., & Loria, A. S. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00950-5 · Cited by 48
Wang, W., Davis, P. B., Qi, X., Gurney, M. E., Perry, G. L., Volkow, N. D., Kaelber, D. C., & Xu, R. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251351329 · Cited by 38
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
Gaddy, A. R., Elrggal, M. E., Madariaga, H. M., Kelly, A., Lerma, E. V., & Colbert, G. B. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101848 · Cited by 46
Furth, S. L., Colhoun, H. M., Kanbay, M., Kukla, A., Lim, L., MacLaughlin, H. L., Navaneethan, S. D., Shroff, R. C., Stenvinkel, P., Cheung, M., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.09.019 · Cited by 55
Self-citationMisrepresentation of semaglutide in social media
Propfe, L. E., & Seifert, R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04403-5 · Cited by 54
Semaglutide-associated kidney injury
Begum, F., Chang, K., Kapoor, K., Vij, R. S., Phadke, G. M., Hiser, W. M., Wanchoo, R., Sharma, P., Sutaria, N., & Jhaveri, K. D. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae250 · Cited by 38
Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Rosenstock, J., Rossing, P. R., Vaduganathan, M., BRINKER, M. D., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf022 · Cited by 38
“…mean eGFR (mL/min/1.73 m 2 ) in CONFIDENCE is similar to that in in CREDENCE [(NCT02065791) 56.2], it is higher than in FIDELIO-DKD (44.3), EMPA-KIDNEY [(NCT03594110) 36.0], DAPA-CKD [(NCT03036150) 43.8], FLOW (47.0) and MOSAIC [(NCT04026165) 35.0], but lower than in FIGARO-DKD (67.8) [21 –27 ].”
InfluentialSelf-citationBailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 42
“In the FLOW trial which enrolled T2DM patients with CKD and albuminuria (eGFR 25 – 75 ml /min/ 1.73 m 2 and UACR 100 – 5000 mg/g), semaglu-tide (1 mg QW for 3.4 years) reduced UACR by 38 % and slowed the rate of decline in eGFR by 1.16 ml/min/ 1.73 m 2 [61].”
InfluentialChaudhry, K., & Karalliedde, J. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15765 · Cited by 42
“…once-weekly use of the GLP-1 receptor agonist semaglutide, studying 3533 participants with an eGFR ≥ 25 and ≤ 75 mL/min and uACR >100 mg/g. 51 The residual risk (as defined by proportion of people progressing to the primary outcome in each treatment group) and relative risk reduction…”
Lee, S. A., Verhoeff, R., Hullekes, F. E., Hansrivijit, P., de Bruin, R. W. F., Porte, R. J., & Riella, L. V. (2025) · Transplantation · doi:10.1097/tp.0000000000005496 · Cited by 43
Lan, N. S. R., Dwivedi, G., Fegan, P. G., Game, F. L., & Hamilton, E. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02527-1 · Cited by 42
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 35
“…as improved symptoms and physical functioning in heart failure with preserved ejection fraction (HFpEF), as demonstrated by the STEP-HFpEF trial [202], and the 24% reduced risk of major kidney adverse effects and 18% reduced risk of MACE reported recently in the results of the FLOW study [203].”
Vanek, L., Kurnikowski, A., Krenn, S., Mussnig, S., & Hecking, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15967 · Cited by 28
“30,31 These trials included patients without severe kidney impairment, whereas data on GLP1-RA treatment in patients with kidney failure or kidney transplant recipients remain scarce.”
Risk-directed management of chronic kidney disease
Blum, M. F., Neuen, B. L., & Grams, M. E. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00931-8 · Cited by 39
“%) in people with CKD and type 2 diabetes 85 .”
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure
Heerspink, H. J. L., Collier, W., Chaudhari, J., Miao, S., Tighiouart, H., Appel, G. B., Caravaca‐Fontán, F., Floege, J., Hannedouche, T. P., Imai, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04057-z · Cited by 50
“In a sensitivity analysis, we included two recent studies for which we received from the clinical trial investigators only tabular data but not individual participant data 17,18 .”
Self-citationLonghitano, E., Calabrese, V., Casuscelli, C., Carlo, S. D., Maltese, S., Romeo, A., Calanna, M., Conti, G., & Santoro, D. (2024) · Medicina · doi:10.3390/medicina60111821 · Cited by 46
“The study showed, among 3533 randomized participants (1767 in the semaglutide group and 1766 in the placebo group), a 40% reduction in the UACR in the semaglutide group compared to a 12% reduction in the placebo group after 104 weeks [61].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
Mesangial Cells in Diabetic Kidney Disease: From Mechanisms to Therapeutic Implications
Li, F., Feng, Y., Ren, Q., Fu, P., & Ma, L. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.114907 · Cited by 36
“…or a sustained eGFR <15 mL/min/1.73 m 2 ], ≥50% decline in the eGFR, or kidney/cardiovascular-related death) by 24% (HR 0.76, 95% CI 0.66-0.88; P=0.0003) in patients with type 2 diabetes and CKD, with 331 versus 410 first events occurring in the semaglutide and placebo groups, respectively [182].”
InfluentialCardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Lee, C. J. M., Kosyakovsky, L. B., Khan, M. S., Wu, F., Chen, G., Hill, J. A., Ho, J. E., Foo, R., & Zannad, F. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325602 · Cited by 40
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Shah, B. R., BAJAJ, H. S., Butalia, S., Dasgupta, K., Eurich, D. T., Jain, R., Leung, K., Mansell, K. D., & Simpson, S. H. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.002 · Cited by 44
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 33
A Comprehensive Analysis of Diabetic Complications and Advances in Management Strategies
IWASAKI, H. O., Yagyu, H., & Shimano, H. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65551 · Cited by 51
“However, a recently published FLOW trial showed that semaglutide effectively reduced end-stage kidney events in patients with overt nephropathy, similar to SGLT2 inhibitors 20) .”
Lin, L., Chen, J., Huang, T. T.-M., & Wu, V. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02649-0 · Cited by 36
“The recently published FLOW trial, which specifically targeted T2DM patients with CKD and used kidney-specific primary endpoints, has solidified the efficacy of GLP-1 RAs in slowing CKD progression [58].”
Lim, C.-E., Pasternak, B., Eliasson, B., & Ueda, P. (2025) · Diabetologia · doi:10.1007/s00125-025-06439-x · Cited by 27
Ko, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 59
Bozkurt, B., Rossignol, P., & Vassalotti, J. A. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3683 · Cited by 34
Garg, S. V., Kaur, G., Renner, D. C., Lanning, M. S., Mason, E., Beatson, C. R., Ciesco, K., & Snell‐Bergeon, J. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0481 · Cited by 33
The expanding benefits of GLP-1 medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102214 · Cited by 42
Fountoulakis, N., Miyamoto, Y., Pavkov, M. E., Karalliedde, J. J., & Maltese, G. (2024) · Diabetic Medicine · doi:10.1111/dme.15464 · Cited by 31
The prevention and management of chronic kidney disease among patients with metabolic syndrome
Zhu, D., Judge, P. K., Wanner, C., Haynes, R., & Herrington, W. G. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.021 · Cited by 38
MASLD, MASH, and the CKM Spectrum
Zannad, F. M., Khan, M. S., Bansal, N., Böhm, M., Francque, S., Girerd, N., Januzzi, J. L., Miller, V., Piché, M., Ratziu, V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.015 · Cited by 40
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 45
“…once weekly) [53], Harmony Outcomes (albiglutide) [54], ELIXA (lixisenatide) [55], AMPLITUDE-O (efpeglenatide) [56], and FLOW (semaglutide)[48] —have further enriched the evidence base, each contributing distinct insights due to differences in trial design, patient populations, and…”
Hsiao, F., Tan, E. C.-H., Meng, L.-C., Lin, Y., Chen, H., Guan, S.-T., Tarng, D., Wang, C., & Chen, L. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.07.004 · Cited by 28
From cardiorenal to cardiovascular–kidney–metabolic syndromes
Braunwald, E. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae775 · Cited by 32
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Chen, X., Zhang, X., Xiang, X., Fang, X., & Feng, S. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01497-4 · Cited by 32
“Among the 9 studies, 1 study incorporated standard treatment for T2DM in both the treatment and control groups [20], and another study included SGLT2 inhibitors in part of the treatment and control groups [22].”
Gonzalez-Rellan, M. J., Riobello, C., Fang, S., da Silva, E. M., Koehler, J. A., Shang, R., Hammoud, R., Cao, X., Varela‐Rey, M., & Drucker, D. J. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.03.011 · Cited by 47
Moiz, A., Zolotarova, T., Filion, K. B., & Eisenberg, M. J. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpaf205 · Cited by 26
KHADKE, S., KUMAR, A., BHATTI, A., DANI, S. S., AL-KINDI, S., NASIR, K., VIRANI, S. S., UPADHYAY, J., GARCIA-BANIGAN, D. C., ABRAHAM, S., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.10.448 · Cited by 25
Petta, S., Kim, K., Targher, G., Romeo, S., Sookoian, S. C., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70407 · Cited by 36
“…was superior to placebo in reducing the risk of major kidney disease events (HR 0.79; 95% CI 0.66–0.94), i.e., a composite of the onset of kidney failure, at least a 50% reduction in eGFR from baseline, or death from kidney-related causes, in 3533 patients with T2D and chronic kidney disease [51].”
InfluentialRenoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Chen, J., Cooper, M., & Coughlan, M. T. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101641 · Cited by 35
Lai, H.-W., See, C. Y., Chen, J.-Y., & Wu, V.-C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02364-2 · Cited by 25
“A clinical trial [FLOW trial, NCT03819153] on the efficacy of GLP-1RAs in diabetic patients with CKD showed a 25% reduction in kidney disease progression after GLP-1RAs use [16].”
BackgroundMethodShokravi, A., Seth, J., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02900-8 · Cited by 41
Aroda, V. R., Jørgensen, N. B., Kumar, B., Lingvay, I., Laulund, A. S., Buse, J. B., & trial investigators (2025) · Diabetes Care · doi:10.2337/dc24-2425 · Cited by 25
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Weiskirchen, R., & Lonardo, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70003 · Cited by 30
Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
Rossing, P. R., Hansen, T. W., & Kümler, T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15747 · Cited by 36
“20 Importantly, in CKD, SGLT2 inhibitors and GLP-1 receptor agonists have now demonstrated organ-protective and lifesaving benefits in CKD regardless of the glucose-lowering effect.”
Self-citationMarassi, M., & Fadini, G. P. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.11.005 · Cited by 27
The real‐life experiences of people living with overweight and obesity: A psychosocial perspective
Flint, S. W., Vázquez‐Velázquez, V., Brocq, S. L., & Brown, A. C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16255 · Cited by 35
The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis
Sasaki, T., Giang, S. M.-L., Wu, J., Yokoo, T., Gallagher, M., Bellomo, R., & Wang, Y. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf193 · Cited by 41
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
New insights in the treatment of DKD: recent advances and future prospects
Zhao, M., Cao, Y., & Ma, L. (2025) · BMC Nephrology · doi:10.1186/s12882-025-03953-3 · Cited by 34
“Among the available GLP-1RAs options, dulaglutide, semaglutide, and the long-acting liraglutide have exhibited notable renal protective properties and are suitable for use as hypoglycemic agents in T2DM patients with renal impairment [44, 45].”
Bonaca, M. P., Catarig, A., Hansen, Y., Houlind, K. C., Ramesh, C. K., Ludvik, B. H., Nordanstig, J., Rasouli, N., Sourij, H., & Verma, S. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae071 · Cited by 26
Gastrointestinal Motility Effects of GLP-1 Receptor Agonists
Bellavance, D. R., Chua, S. G., & Mashimo, H. L. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00995-3 · Cited by 33
Grams, M. E., & Melamed, M. L. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02684 · Cited by 30
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Kanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 47
Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17037 · Cited by 28
“Similarly, the FLOW trial, which included individuals with T2DM and albuminuric kidney disease, showed that once-weekly semaglutide (1 mg) not only improved cardiovascular outcomes and survival rates but also reduced the incidence of kidney-specific adverse outcomes [36].”
Colombijn, J. M. T., de Leijer, J. F., Visseren, F. L. J., Verhaar, M. C., van Raalte, D. H., Sattar, N. A., Vernooij, R. W. M., & van Sloten, T. T. (2025) · Diabetologia · doi:10.1007/s00125-025-06565-6 · Cited by 37
Bilson, J., Hydes, T., McDonnell, D., Buchanan, R. M., Scorletti, E., Mantovani, A., Targher, G., & Byrne, C. D. (2024) · Liver International · doi:10.1111/liv.16159 · Cited by 31
“In 2024, semaglutide was also shown to reduce the risk of clinically important renal outcomes and death from cardiovascular causes in patients with T2D and CKD [25].”
Fadini, G. P., Longato, E., Morieri, M. L., Bonora, E., Consoli, A., Fattor, B., Rigato, M., Turchi, F., Prato, S. D., Avogaro, A., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06251-z · Cited by 37
Delrue, C., & Speeckaert, M. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179351 · Cited by 28
“In the recently published FLOW trial, semaglutide lowered the risk of major renal complications and cardiovascular death in individuals with T2D and chronic kidney disease (CKD) [44].”
BackgroundFernando, K., Connolly, D. L., Darcy, E., Evans, M., Hinchliffe, W., Holmes, P., & Strain, W. D. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01738-3 · Cited by 32
“Additionally, subcutaneous semaglu-tide has demonstrated cardiorenal benefits in the recently published FLOW trial (NCT03819153), reducing the risk of major kidney disease events and cardiovascular mortality in patients with T2D and CKD [30].”
Georgianos, P. I., Vaios, V., Koufakis, T., & Liakopoulos, V. (2024) · Drugs · doi:10.1007/s40265-024-02091-8 · Cited by 27
“K I DN E Y [ 18 ] F I D E L I O - DKD [ 31 ] F I GA R O - DKD [ 32 ] F L O W [ 39 ] Y ea r – [15].”
Influential2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 167
Stone, C. R., Harris, D. D., Broadwin, M., Kanuparthy, M., Nho, J.-W., Yalamanchili, K., Hamze, J., Abid, M. R., & Sellke, F. W. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321850 · Cited by 26
Singh, V., Sun, J. M., Cheng, S. C., Kwan, A. C., & Velazquez, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03352-y · Cited by 37
“RCTs in T2DM of sema-glutide and liraglutide have shown reduction in prespecified renal endpoints [157, 158].”
Rasalam, R. R., Sindone, A. P., Deed, G., Audehm, R. G., & Atherton, J. J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15205 · Cited by 28
Rashid, A. M., Khan, M. S., Cherney, D. Z. I., Mehta, A. N., Rangaswami, J., Shafi, T., & Butler, J. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000752 · Cited by 25
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.